FDA approves new pancreatic cancer drug that could extend patients' lives
Source: www.cbsnews.com ·
Section: headlines ·
Bias: Left
· Published: Thu, 27 Aug 2026 00:07:22 GMT
Patients taking the first-of-a-kind pill, called daraxonrasib, lived for a median of 13.2 months compared with 6.7 months for chemotherapy recipients, studies showed.
Read the full article at www.cbsnews.com →
The same story across the political spectrum (2 sources)
← Back to FlashTopics.com